Cargando…

Markedly divergent effects of Ouabain on a Temozolomide-resistant (T98G) vs. a Temozolomide-sensitive (LN229) Glioblastoma cell line

BACKGROUND: Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor with poor prognosis. GMB are highly recurrent mainly because of radio- and chemoresistance. Radiotherapy with Temozolomide (TMZ) is until today the golden standard adjuvant therapy, however, the optimal treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Weidemann, Heidrun, Feger, Daniel, Ehlert, Jan E., Menger, Marcus M., Krempien, Robert C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968366/
https://www.ncbi.nlm.nih.gov/pubmed/36840822
http://dx.doi.org/10.1007/s12672-023-00633-2
_version_ 1784897490078662656
author Weidemann, Heidrun
Feger, Daniel
Ehlert, Jan E.
Menger, Marcus M.
Krempien, Robert C.
author_facet Weidemann, Heidrun
Feger, Daniel
Ehlert, Jan E.
Menger, Marcus M.
Krempien, Robert C.
author_sort Weidemann, Heidrun
collection PubMed
description BACKGROUND: Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor with poor prognosis. GMB are highly recurrent mainly because of radio- and chemoresistance. Radiotherapy with Temozolomide (TMZ) is until today the golden standard adjuvant therapy, however, the optimal treatment of recurrent glioblastoma remains controversial. Ouabain belongs to the Cardiotonic Steroids (CTS) the natural ligands of the Na/K-ATPase (NKA). It is established that the NKA represents a signal transducer with either stimulating or inhibiting cell growth, apoptosis, migration and angiogenesis. Over the last decade evidence grew that CTS have anti-tumor properties especially in GBM. AIM: Proceeding from recent studies we wanted to further demonstrate a divergent effect of Ouabain on a TMZ-resistant (T98G) as compared to a TMZ-sensitive (LN229) GBM cell line. METHODS: We analyzed the effect of Ouabain on cell migration and plasma cell membrane potential (PCMP) in the LN229 and T98G GBM cell line as well as underlying mechanisms (Bcl-2 and p-Akt/pan-Akt expression). Moreover, we analyzed the anti-angiogenic effect of Ouabain on human umbilical vein endothelial cells (HUVECs). RESULTS: T98G cells showed a significant inhibition of cell migration and a significant depolarization of the PCMP at similar Ouabain concentrations (IC50 = 1.67 × 10(–7) M) resp. (IC50 = 2.72 × 10(–7) M) with a strong inverse correlation (R(2) = 0.95). In contrast, LN229 cells did not respond to Ouabain in these assays at all. Similarly, only T98G but not LN229 cells revealed Bcl-2 down-regulation at nanomolar Ouabain concentrations. This unique response to Ouabain is associated with a down-regulation of pan-Akt in T98G cells 24 h after Ouabain (1.0 × 10(–6) M) treatment. For the first time, the anti-angiogenic effect of Ouabain on HUVEC cells (IC50 = 5.49 × 10(–8) M) was demonstrated which correlated strongly with the anti-migratory effect (R(2) = 0.85). CONCLUSION: The TMZ-resistant T98G cell line as compared to the TMZ-sensitive LN229 cell line shows a high sensitivity towards Ouabain. We consider it as a promising new compound especially in recurrent GBM to overcome the resistance to TMZ and irradiation.
format Online
Article
Text
id pubmed-9968366
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-99683662023-02-27 Markedly divergent effects of Ouabain on a Temozolomide-resistant (T98G) vs. a Temozolomide-sensitive (LN229) Glioblastoma cell line Weidemann, Heidrun Feger, Daniel Ehlert, Jan E. Menger, Marcus M. Krempien, Robert C. Discov Oncol Research BACKGROUND: Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor with poor prognosis. GMB are highly recurrent mainly because of radio- and chemoresistance. Radiotherapy with Temozolomide (TMZ) is until today the golden standard adjuvant therapy, however, the optimal treatment of recurrent glioblastoma remains controversial. Ouabain belongs to the Cardiotonic Steroids (CTS) the natural ligands of the Na/K-ATPase (NKA). It is established that the NKA represents a signal transducer with either stimulating or inhibiting cell growth, apoptosis, migration and angiogenesis. Over the last decade evidence grew that CTS have anti-tumor properties especially in GBM. AIM: Proceeding from recent studies we wanted to further demonstrate a divergent effect of Ouabain on a TMZ-resistant (T98G) as compared to a TMZ-sensitive (LN229) GBM cell line. METHODS: We analyzed the effect of Ouabain on cell migration and plasma cell membrane potential (PCMP) in the LN229 and T98G GBM cell line as well as underlying mechanisms (Bcl-2 and p-Akt/pan-Akt expression). Moreover, we analyzed the anti-angiogenic effect of Ouabain on human umbilical vein endothelial cells (HUVECs). RESULTS: T98G cells showed a significant inhibition of cell migration and a significant depolarization of the PCMP at similar Ouabain concentrations (IC50 = 1.67 × 10(–7) M) resp. (IC50 = 2.72 × 10(–7) M) with a strong inverse correlation (R(2) = 0.95). In contrast, LN229 cells did not respond to Ouabain in these assays at all. Similarly, only T98G but not LN229 cells revealed Bcl-2 down-regulation at nanomolar Ouabain concentrations. This unique response to Ouabain is associated with a down-regulation of pan-Akt in T98G cells 24 h after Ouabain (1.0 × 10(–6) M) treatment. For the first time, the anti-angiogenic effect of Ouabain on HUVEC cells (IC50 = 5.49 × 10(–8) M) was demonstrated which correlated strongly with the anti-migratory effect (R(2) = 0.85). CONCLUSION: The TMZ-resistant T98G cell line as compared to the TMZ-sensitive LN229 cell line shows a high sensitivity towards Ouabain. We consider it as a promising new compound especially in recurrent GBM to overcome the resistance to TMZ and irradiation. Springer US 2023-02-25 /pmc/articles/PMC9968366/ /pubmed/36840822 http://dx.doi.org/10.1007/s12672-023-00633-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Weidemann, Heidrun
Feger, Daniel
Ehlert, Jan E.
Menger, Marcus M.
Krempien, Robert C.
Markedly divergent effects of Ouabain on a Temozolomide-resistant (T98G) vs. a Temozolomide-sensitive (LN229) Glioblastoma cell line
title Markedly divergent effects of Ouabain on a Temozolomide-resistant (T98G) vs. a Temozolomide-sensitive (LN229) Glioblastoma cell line
title_full Markedly divergent effects of Ouabain on a Temozolomide-resistant (T98G) vs. a Temozolomide-sensitive (LN229) Glioblastoma cell line
title_fullStr Markedly divergent effects of Ouabain on a Temozolomide-resistant (T98G) vs. a Temozolomide-sensitive (LN229) Glioblastoma cell line
title_full_unstemmed Markedly divergent effects of Ouabain on a Temozolomide-resistant (T98G) vs. a Temozolomide-sensitive (LN229) Glioblastoma cell line
title_short Markedly divergent effects of Ouabain on a Temozolomide-resistant (T98G) vs. a Temozolomide-sensitive (LN229) Glioblastoma cell line
title_sort markedly divergent effects of ouabain on a temozolomide-resistant (t98g) vs. a temozolomide-sensitive (ln229) glioblastoma cell line
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968366/
https://www.ncbi.nlm.nih.gov/pubmed/36840822
http://dx.doi.org/10.1007/s12672-023-00633-2
work_keys_str_mv AT weidemannheidrun markedlydivergenteffectsofouabainonatemozolomideresistantt98gvsatemozolomidesensitiveln229glioblastomacellline
AT fegerdaniel markedlydivergenteffectsofouabainonatemozolomideresistantt98gvsatemozolomidesensitiveln229glioblastomacellline
AT ehlertjane markedlydivergenteffectsofouabainonatemozolomideresistantt98gvsatemozolomidesensitiveln229glioblastomacellline
AT mengermarcusm markedlydivergenteffectsofouabainonatemozolomideresistantt98gvsatemozolomidesensitiveln229glioblastomacellline
AT krempienrobertc markedlydivergenteffectsofouabainonatemozolomideresistantt98gvsatemozolomidesensitiveln229glioblastomacellline